It has been shown to suppress FTO activity, increase the global m6A modification level and exert antitumor effects in AML without IDH1/2 mutations by decreasing the mRNA stability of MYC/CEBPA, leading to the suppression of related pathways [53]. The gene discussed is MYC; the disease is acute myeloid leukemia.